90Y-ibritumomab tiuxetan (Zevalin)
Sponsors
AHS Cancer Control Alberta, Oslo University Hospital
Conditions
LymphomaMantle Cell Lymphoma
Phase 2
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL
WithdrawnNCT00414089
Updated: 2016-02-15
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
CompletedNCT00514475
Start: 2005-11-30End: 2009-06-30Updated: 2012-05-04